Metformin is an insulin sensitizer molecule used for the treatment of infertility in women with polycystic ovary syndrome and insulin resistance. It modulates the reproductive axis, affecting the release of gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH). However, metformin's mechanism of action in pituitary gonadotropin-secreting cells remains unclear. Adenosine 5 0 monophosphate-activated protein kinase (PRKA) is involved in metformin action in various cell types. Here, we investigated the effects of metformin on gonadotropin secretion in response to activin and GnRH in primary rat pituitary cells (PRP), and studied PRKA in rat pituitary. In PRP, metformin (10 mM) reduced LH and folliclestimulating hormone (FSH) secretion induced by GnRH (10 À8 M, 3 h), FSH secretion, and mRNA FSHbeta subunit expression induced by activin (10 À8 M, 12 or 24 h). The different subunits of PRKA are expressed in pituitary. In particular, PRKAA1 is detected mainly in gonadotrophs and thyrotrophs, is less abundant in lactotrophs and somatotrophs, and is undetectable in corticotrophs. In PRP, metformin increased phosphorylation of both PRKA and acetyl-CoA carboxylase. Metformin decreased activin-induced SMAD2 phosphorylation and GnRH-induced mitogen-activated protein kinase (MAPK) 3/1 (ERK1/2) phosphorylation. The PRKA inhibitor compound C abolished the effects of metformin on gonadotropin release induced by GnRH and on FSH secretion and Fshb mRNA induced by activin. The adenovirus-mediated production of dominant negative PRKA abolished the effects of metformin on the FSHbeta subunit mRNA and SMAD2 phosphorylation induced by activin and on the MAPK3/1 phosphorylation induced by GnRH. Thus, in rat pituitary cells, metformin decreases gonadotropin secretion and MAPK3/1 phosphorylation induced by GnRH and FSH release, FSHbeta subunit expression, and SMAD2 phosphorylation induced by activin through PRKA activation.
INTRODUCTION
Metformin is an insulin-sensitizing drug, introduced for the treatment of anovulatory infertility in polycystic ovary syndrome (PCOS) patients with glucose intolerance and/or insulin resistance [1] but with varying degrees of success [2] . PCOS affects 5%-10% of women of childbearing age [3] . It is characterized by infertility, anovulation, androgen excess, polycystic ovaries, elevated luteinizing hormone (LH) levels, and increased LH:follicle-stimulating hormone (FSH) ratio [3] . Raised plasma insulin levels are now recognized as a feature of PCOS, and hyperinsulinism has been shown to contribute to ovarian overproduction of androgens [4] . The exact mechanism through which metformin acts in PCOS is still unknown and thus the variable effects that are seen are not explicable [2] . Its various mechanisms of action include inhibition of gluconeogenesis in the liver and stimulation of peripheral uptake of glucose [5] . Peripheral effects of metformin, dependent and/or independent of its insulin-sensitizing action, have been also found in several experimental studies [6, 7] . In particular, previous data have suggested a specific effect of metformin on ovaries, showing that PCOS patients ovulating under treatment have an improved ovarian artery blood flow and better dominant follicle and corpus luteum vascularization [6] . Metformin is also able to exert direct effects on the ovary, by inhibiting, for example, basal and insulin-stimulated estradiol and progesterone production by granulosa cells in various species including human [8, 9] . In vivo, treatment with metformin reduces the stimulated activity of several steroidogenic enzymes without a reduction in circulating insulin in women with PCOS [10] . Some studies indicate that metformin treatment is also able to modulate the release of LH [11, 12] and lowered LH secretion in PCOS women [13, 14] . These results suggest that metformin could affect pituitary gonadotropin-secreting cells. However, very little is known about the effects of metformin and the molecular mechanisms associated with this drug in the pituitary. Activation of adenosine 5 0 monophosphate-activated protein kinase (PRKA) is a speculative mechanism whereby metformin could exert its action on these target cells. Recently, it has been reported that a singlenucleotide polymorphism in STK11 (or LKB1), a kinase that catalyzes the AMP-activated protein kinase complex, influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess [15] .
PRKA is a major cellular energy sensor and a master regulator of metabolic homeostasis. It is a heterotrimeric enzyme comprised of a catalytic (a1 or a2) subunit and two regulatory (b1 or b2 and c1, c2, or c3) subunits, all of which are encoded by separate genes, making it possible to form a total of 12 complexes [16] . PRKA is mainly activated by two distinct signals: a Ca 2þ -dependent pathway mediated by CAMKKb and an AMP-dependent pathway mediated by STK11 [17] . Both STK11 and CAMKKb phosphorylate PRKA on Thr172 on the a subunit. A number of physiological processes have been shown to stimulate PRKA, including conditions that lead to alterations of the intracellular AMP:ATP ratio (e.g., hypoxia, glucose deprivation) and calcium concentration, as well as the action of various hormones, cytokines, and adipokines. The effects of PRKA activation are pleiotropic in key metabolically relevant tissues, such as liver, skeletal muscle, and adipose tissue, but also in reproductive tissues, including hypothalamus, pituitary, and ovary. In dispersed primary rat hypothalamic neuronal cell cultures, metformin inhibited PRKA activity in hypothalamic neurons, thus modulating the expression of the orexigenic peptide NPY [18] . Our laboratory has also shown that metformin inhibits gonadotropin-releasing hormone (GnRH) release from immortalized hypothalamic GT1-7 cells via PRKA activation, whereas compound C (Comp C), a well-known PRKA inhibitor, completely eliminates this effect [19] . Furthermore, adiponectin has been shown to reduce LH secretion in pituitary gonadotrophs in a PRKAdependent manner [20] . Thus, PRKA could be a crucial kinase regulating GnRH secretion in the hypothalamus and gonadotropin secretion in the pituitary.
In the present study, we investigate the effects and the molecular mechanism of metformin and potential involvement of PRKA on LH and FSH secretions in the presence or absence of activin or GnRH in rat primary pituitary cells. The results support the concept that metformin affects LH and FSH secretion via PRKA.
MATERIALS AND METHODS

Hormones and Reagents
The radionucleotide [a 32 P] dCTP (6000 Ci/mmol) was obtained from Perkin Elmer. Recombinant human activin and follistatin were purchased from R&D Systems. Recombinant human GnRH, metformin, and Comp C were from Sigma. Dulbecco modified Eagle medium (DMEM), penicillin, and streptomycin were purchased from Invitrogen. Thymidine methyl-3 H was purchased from Perkin Elmer.
Antibodies
Rabbit polyclonal antibodies to PRKAB1/2, PRKAG1, PRKAG2, PRKAG3, phospho-PRKAA Thr172, acetyl-CoA carboxylase (ACACA), AKT, phospho-mitogen-activated protein kinase (MAPK) 3/MAPK1, and phospho-MAPK14 were purchased from Cell Signaling Technology. Rabbit polyclonal antibodies to MAPK1, phospho-AKT (Ser473), and MAPK14 were purchased from Santa Cruz Biotechnology. Rabbit polyclonal antibodies to SMAD2, phospho-SMAD2 (Ser465/467), PRKAA1, PRKAA2, and phospho-ACACA Ser79 were obtained from Upstate Biotechnology. Mouse monoclonal antibody to vinculin (VCL) was obtained from Sigma. All antibodies were used at 1/1000 dilution in Western blotting. For immunohistochemistry, sheep polyclonal antibody to PRKAA1 was a gift from D.G. Hardie (University of Dundee, U.K.). Rabbit polyclonal antibodies to rat LHB, TSHB, PRL, GH, and ACTH were courtesy-provided in 1990 by Dr. Parlow from NIDDK, National Hormone Pituitary Program, Bethesda, MD.
Animals, Isolation, and Culture of Pituitary Rat Primary Cells
All procedures were approved by the Agricultural Agency and the Scientific Research Agency and were conducted in accordance with the guidelines for Care and Use of Agricultural Animals in Agricultural Research and Teaching. Three-week-old immature female rats of the Wistar strain were purchased from Janvier Laboratories. They were housed in controlled temperature and photoperiod (14L:10D and lights-on from 0600 to 2000 h) conditions. The animals had ad libitum access to food and water. Pituitary rat primary cells were prepared by collagenase/DNase dispersion of the diced tissue from freshly obtained rat pituitary glands. Cells were resuspended in DMEM without phenol red containing 5% fetal bovine serum (FBS), 100 units/ ml penicillin, and 100 lg/ml streptomycin and then seeded in 48-well culture plates at a concentration of 4 3 10 5 cells/well or in 6-well tissue culture plates at a concentration of 3 3 10 6 cells/well. Cells were allowed to recover for 2 days. After two washes in medium without serum and an equilibration period of 2-3 h, test substances were added at the indicated concentrations and incubation times. All cultures were performed under a water-saturated atmosphere of 95% air:5% CO 2 at 378C.
Gonadotropin Measurements
Concentrations of LH and FSH released into the culture medium of pituitary rat primary cells were measured by radioimmunoassay using rat reagents (rat LH: rLH-RP-3; rat FSH: rFSH-RP-2) supplied by NIDDK with samples for each hormone evaluated in duplicate in one assay [21] . The minimum detectable concentrations were 0.1 ng/ml for LH and 1 ng/ml for FSH, and the intra-assay coefficients of variation were ,5%.
Thymidine Incorporation into Pituitary Rat Primary Cells
Pituitary rat primary cells (2 3 10 5 viable cells/500 ll) were cultured in 24-well dishes in DMEM without phenol red containing 5% FBS during 48 h and were then serum starved for 24 h, followed by the addition of 1 lCi/ll of [ 3 H] thymidine (Amersham Life Science) in the presence or absence of metformin (10 mM), activin (10 À8 M), or GnRH (10 À8 M for the last 3 h) in serum-free medium. Cultures were maintained at 378C under 5% CO 2 in air. After 24 h of culture, excess thymidine was removed by washing twice with phosphatebuffered saline (PBS), fixed with cold trichloroacetic acid 50% for 15 min, and lysed by NaOH 0.5 N. The radioactivity was determined by scintillation fluid (Packard Bioscience) counting in a b-photomultiplier.
Adenoviruses and Infection of Pituitary Rat Primary Cells
Dominant negative PRKA adenovirus (Ad.aDN) was constructed from PRKAA1 carrying the Asp-157 to Ala (D157A) mutation as previously described [22] . Recombinant adenovirus was propagated in HEK293 cells, purified by cesium chloride density centrifugation, and stored as previously described [22] . Pituitary rat primary cells were preinfected with 100 pfu/cell adenovirus in serum-starved DMEM during 16 h and then cultured for 24 h with metformin (10 mM) and/or activin (10 À8 M) and/or GnRH (10 À8 M) in serum-free medium as indicated in figure legends. Preliminary studies revealed that within 16 h of infection (100 pfu/cell) with a green fluorescent protein (GFP)-expressing virus, 90% of pituitary cells expressed green fluorescent protein (data not shown).
Immunoblotting
Total proteins from rat pituitary cells were extracted on ice in lysis buffer (10 mM Tris [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% Igepal; Sigma) containing various protease inhibitors (2 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin) and phosphatase inhibitors (100 mM sodium fluoride, 10 mM sodium pyrophosphate, 2 mM sodium orthovanadate; Sigma). Lysates were centrifuged at 13 000 3 g for 20 min at 48C, and the protein concentration in the supernatants was determined using a colorimetric assay (kit BC Assay, Uptima Interchim). Proteins (50 lg) were resolved by SDS-PAGE and transferred to nitrocellulose membranes. Cell extracts were subjected to electrophoresis on 12% (w:v) SDS-polyacrylamide gel under reducing conditions. The proteins were then electrotransferred onto nitrocellulose membranes (Schleicher and Schuell) for 1 h 30 min at 80 V. Membranes were incubated for 1 h at room temperature with Tris-buffered saline (TBS; 2 mM Tris-HCl, pH 8.0, 15 mM NaCl, pH 7.6) containing 5% nonfat dry milk powder (NFDMP) and 0.1% Tween-20 to saturate nonspecific sites. Then membranes were incubated overnight at 48C with appropriate primary antibodies (final dilution 1:1000) in TBS containing 0.1% Tween-20 and 5% NFDMP. After washing in TBS-0.1% Tween-20, the membranes were incubated for 2 h at room temperature with a horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG (final dilution 1:10 000; Diagnostic Pasteur) in TBS-0.1% Tween-20. After washing in TBS-0.1% Tween-20, the signal was detected by enhanced chemiluminescence (Amersham Pharmacia Biotech). The films were analyzed and signals quantified with the software Scion Image (4.0.3.2 version).
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Immunohistochemistry
After fixation and dehydration, rat pituitaries were embedded in paraffin wax. Sections (5-lm thickness) were dewaxed and rehydrated in xylene, then in decreasing concentrations of alcohol (100%, 90%, and 75%). Antigen retrieval was performed by steaming the sections in a microwave in citrate buffer (0.01 M, pH 6.0) for 5 min, then cooling them down for 20 min. After two 5-min washes in PBS, sections were incubated at 48C overnight with the sheep polyclonal anti-PRKAA1 diluted 1:200 in PBS containing 5% bovine serum albumin (PBS/BSA). Negative controls were performed by using knockout (KO) PRKAA1 mouse pituitary slides in comparison with wild-type (WT) mouse pituitary. The pituitaries of these mice were provided by B. Viollet (Inserm U1016, Institut Cochin, Paris, France [23] ). After washes in PBSTween 20 (0.05% PBST) and PBS, slides were incubated in goat anti-sheep Alexa 488 (Invitrogen) and diluted at 1:5000 in PBS for 1 h. After washes in PBS, slides were blocked in PBS/BSA for 30 min. Sections were then incubated at room temperature with rabbit polyclonal antibodies directed against rLHB, rPRL, rGH, rTSH, or rACTH diluted in PBS/BSA at 1:100. Negative controls were performed by replacing the antibodies with normal rabbit serum. After washes in PBST and PBS, slides were incubated with goat anti-rabbit Alexa 633 diluted at 1:500 for 60 min. After three 5-min washes in PBS, sections were mounted with Vectashield (Vector Laboratories). Pictures were taken with a Zeiss 340 dry objective.
RNA Isolation and RT-PCR
Total RNA was extracted from whole rat pituitary or pituitary rat primary cells using Trizol reagent, according to the procedure outlined by the manufacturer (Invitrogen). RNA was quantified by measuring the absorbance at 260 nm. Samples were stored at À808C until use. RT-PCR was performed to assay expression of various PRKA subunits. Reverse transcription (RT) of 1 lg of total RNA was carried out in a 20-ll reaction mixture containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 200 lM of each deoxynucleotide triphosphate (Amersham), 50 pmol of oligo(dT)15, 5 U of ribonuclease inhibitor, and 15 U of Moloney murine leukemia virus (MMLV) reverse transcriptase. RT reaction was carried out at 378C for 1 h. Single-strand cDNAs were amplified with specific sets of primer pairs designed to amplify parts of different PRKA subunits as described in Table 1 . PCRs were carried out using 2 ll of the RT reaction mixture in a total volume of 50 ll containing 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM MgCl2, 200 mM of each deoxynucleotide triphosphate, 10 pmol of each primer, and 1 U of Taq polymerase. The samples were processed for 35 PCR cycles (958C for 1 min, 588C for 1 min, 728C for 1 min), with a final extension step at 728C for 10 min. PCR products underwent gel electrophoresis on a 1.5% agarose gel; the gel was then stained with ethidium bromide for visualization and the DNAs were extracted from the agarose using the gel extraction kit QIAEX II (Qiagen) and sequenced in both directions using a Dye terminator kit on an ABI Prism automated sequencer, model 377 (Biomolecular Research Facility, University of Virginia, Charlottesville, VA). To evaluate the risk of amplification from genomic DNA potentially present in our total RNA preparations, all samples were amplified by PCR with each primer pair in the absence of reverse transcriptase. RT-PCR consumables were purchased from Sigma, except for MMLV reverse transcriptase and RNase inhibitor (RNasin), which were purchased from Promega.
Northern Blot
Total RNAs from cells (20 lg) were separated by denaturing formaldehyde electrophoresis, transferred to a nylon membrane by capillary action overnight, and hybridized as previously described [24, 25] . The b subunit probes for rat FSH and LH were generated by RT-PCR using the following primers: rat Fshb sense, 5
0 . Membrane-incorporated radioactivity was quantified using a STORM PhosphoImager (Molecular Dynamics). The integrity and the quantification of different transcripts were assessed using the human RNA 18S probe as a control (Ambion).
Statistical Analysis
All experimental data are presented as means 6 SEM. One-way ANOVA was used to test differences. If ANOVA revealed significant effects, the means were compared by Newman test, with P , 0.05 considered significant. In the various graphs, different letters indicate significant differences.
RESULTS
Effects of Metformin Treatment on Basal and GnRHor Activin-Stimulated LH and FSH Secretion in Rat Pituitary Cells
To investigate the effect of metformin treatment on the release of LH and FSH, primary rat pituitary cells were incubated with various concentrations of metformin (0, 1, 5, and 10 mM) for 48 h in the presence or absence of exogenous activin (10 À8 M, 48 h) or GnRH (10 À8 M, during the last 3 h) in serum-free medium. Secretion of both LH (Fig. 1A) and FSH ( Fig. 1B) were not affected by the metformin treatment alone whatever the concentration used. As expected, activin alone (48 h) significantly increased FSH release but did not affect LH release [26, 27] , whereas GnRH increased both LH and FSH secretion ( Fig. 1, A and B ). In the presence of activin (10 À8 M, 48 h) or GnRH (10 À8 M, 3 h), metformin (5 or 10 mM, 48 h) decreased FSH secretion in a dose dependent manner (P , 0.001; Fig. 1B ). Metformin also reduced LH secretion induced by GnRH (Fig. 1A) . Thus, metformin decreased GnRHstimulated LH and FSH secretion and activin-induced FSH release in primary rat pituitary cells.
We next examined whether the inhibitory effect of metformin on activin-induced FSH release was due to effects on the levels of mRNA expression of the b subunit of FSH. As expected, continuous stimulation for 3 h of GnRH did not affect LHb and FSHb subunit mRNA levels [28] (data not shown). Metformin treatment (10 mM, 12 or 24 h) halved the (Fig. 1D) . Thus, the decrease in activin-induced FSH secretion in response to metformin treatment may be due to a reduction in the mRNA expression of the FSHb subunit.
Characterization of PRKA in Rat Pituitary
We next identified PRKA subunit expression in the rat pituitary. RT-PCR analysis with RNA from rat pituitary and from primary rat pituitary cells in culture resulted in the amplification of seven cDNAs. These cDNAs corresponded to fragments of two different isoforms of the catalytic a subunit, PRKAA1 (770 bp) and PRKAA2 (1652 bp); two different isoforms of the regulatory b subunit, PRKAB1 (802 bp) and PRKAB2 (810 bp); and three different isoforms of the regulatory c subunit, PRKAG1 (600 bp), PRKAG2 (620 bp), and PRKAG3 (300 bp) of PRKA ( Fig. 2A) . In the absence of the enzyme, no amplification product was detected after 35 cycles ( Fig. 2A) . Immunoblotting protein extracts revealed the presence of PRKAA1 and PRKAA2 (62 kDa), PRKAB1 (38 kDa), PRKAB2 (34 kDa), PRKAG1 (37 kDa), and PRKAG2 (75 kDa) (Fig. 2B) , showing that the three subunits a, b, and c of PRKA are produced in rat pituitary and in cultured rat pituitary cells. We failed to detect the PRKAG3 subunit with the used antibody.
Immunolocalization with rat pituitary sections confirmed the presence of the catalytic subunit PRKAA1 in various rat pituitary cells (Fig. 3) . A representative picture showing colocalization between PRKAA1 and LH (Fig. 3A) , GH (Fig. 3B) , TSH (Fig. 3C) , and PRL (Fig. 3D ), but not ACTH (Fig. 3E) , is indicated. As a negative control for the PRKAA1 antibody, we performed immunofluorescence with mouse pituitary sections from total KO PRKAA1 [23] and WT mice (Fig. 3E) . PRKAA1 was expressed strongly in gonadotrophs and thyrotrophs and weakly in somatotroph and lactotroph cells, and was undetectable in corticotroph cells (Fig. 3F) . . Different letters indicate significant difference (P , 0.05). C and D) Cells were incubated in serum-free medium in the presence of follistatin (10 À8 M) for 24 h and then treated with metformin (10 mM, 12 or 24 h) in the absence or in the presence of activin (10 À8 M) in serum-free medium. Total RNA was prepared, and Northern blot was carried out using specific rat probes for the b subunits of FSH (C) and LH (D). As a control, the membranes were stripped and reprobed with 18S RNA to confirm equal loading and to determine the metformin effect. The ratios FSHB or LHB:RN18S were calculated. Values represent means 6 SEM (bar) from three independent experiments. Different letters indicate significant difference (P , 0.05). 
PRKA AND METFORMIN EFFECTS IN RAT PITUITARY CELLS
phospho-PRKAA Thr172 antibody specific for phosphorylated catalytic a subunit. Metformin treatment (10 mM) increased PRKAA phosphorylation after 60 and 120 min of incubation (P , 0.05) and in a dose-dependent manner after 120 min of stimulation (Fig. 4, A and B , P , 0.05). We also indirectly assessed the PRKA activity by measuring the phosphorylation of its downstream target, ACACA. Metformin increased the phosphorylation of ACACA on Ser79 in a time-dependent ( Fig. 4C , P , 0.05) and dose-dependent manner (Fig. 4D , P , 0.05); this phosphorylation paralleled that of Thr172 PRKAA (Fig. 4, A and B) . Thus, metformin is able to activate PRKAA in cultured rat pituitary cells.
Effects of Comp C on Metformin-Inhibited LH and FSH Release in Response to GnRH or Activin in Primary Rat Pituitary Cells
To determine whether PRKAA phosphorylation is involved in the inhibition of GnRH or activin-induced gonadotropin release in response to metformin in primary rat pituitary cells, we investigated the effects of Comp C, a well-known inhibitor of PRKA [30] on PRKAA phosphorylation and on LH and FSH secretion. After 2 h of metformin stimulation in serumfree medium, immunoblot analysis confirmed that Comp C treatment (10 lM) significantly decreased PRKAA phosphorylation compared with the control treated with dimethyl sulfoxide (Fig. 5A ). Comp C treatment (10 lM) totally abolished the inhibition of GnRH-induced LH and FSH release and activin-induced FSH release in response to metformin (Fig.  5, B and C) . The viability of rat primary pituitary cells as determined by trypan blue staining was not affected by Comp C treatment (data not shown). Thus, Comp C inhibited PRKAA phosphorylation and abolished the inhibitory effect of metformin on GnRH and activin-induced gonadotropin release.
Effects of Overexpression of Dominant Negative PRKAA1 (Ad.aDN) on Metformin-Inhibited Fshb mRNA Expression in Response to Activin in Primary Rat Pituitary Cells
We next investigated whether the metformin-induced decrease in the level of Fshb mRNA was mediated by PRKA. We used an adenoviral vector (Ad.aDN) to overexpress a dominant-negative PRKAA1 in cultured primary rat pituitary cells and treated these cells with metformin (10 mM) 6 activin (10 À8 M) for 24 h in serum-free medium. Pituitary cells were infected with 100 pfu of Ad.aDN and Ad.GFP (Ad.GFP as a control) adenovirus and were analyzed by Western blotting for production of mutant and endogenous PRKAA subunits (Fig.  6A) . Ad.aDN proteins with 100 pfu were produced abundantly, and they significantly attenuated basal PRKAA Thr172 phosphorylation (Fig. 6A) without affecting cell viability (data not shown). Cell infection with control (Ad.GFP, 100 pfu) had no effect on PRKAA expression or PRKAA Thr172 phosphorylation (Fig. 6A) .
Expression of Ad.aDN in rat pituitary cells strongly reduced the metformin-induced decrease in the production of FSHb subunit mRNA in the presence of activin (Fig. 6B) . The expression of Ad.GFP in the same conditions did not restore these inhibitory effects of metformin (Fig. 6B) . Thus, metformin reduces the mRNA expression of FSHb subunit induced by activin through activation of PRKAA in rat pituitary cells.
Signaling Pathways Involved in the Metformin Effects in Rat Primary Pituitary Cells
As expected [27, [31] [32] [33] [34] [35] , we observed that activin treatment (10 À8 M) increased phosphorylation of SMAD2, AKT, and MAPK3/1 (Fig. 7, A-C) , and GnRH treatment (10 À8 M) increased phosphorylation of MAPK3/1 and MAPK14 (Fig. 7 , D and E) in a time-dependent manner in rat pituitary cells. Metformin (10 mM) significantly inhibited phosphorylation of activin-induced SMAD2 phosphorylation and GnRH-induced MAPK3/MAPK1 phosphorylation (Fig. 8, A and B) . Under the same conditions, phosphorylation levels of AKT and MAPK3/ MAPK1 in response to activin and those of MAPK14 induced by GnRH were unchanged (data not shown). Expression of Ad.aDN in rat pituitary cells totally abolished the metformininduced decrease of SMAD2 phosphorylation in response to activin (Fig. 8C ) and metformin-induced decrease of MAPK3/ MAPK1 in the presence of GnRH (Fig. 8D) . The expression of Ad.GFP did not restore these inhibitory effects of metformin (Fig. 8, C and D) . Thus, metformin-induced PRKAA activation inhibited SMAD2 phosphorylation induced by activin and MAPK3/MAPK1 phosphorylation in response to GnRH in rat pituitary cells.
Effects of Metformin on Rat Pituitary Cell Proliferation and Viability
We also investigated whether or not the dose of metformin used (10 mM) affected the number of pituitary cells in culture, either by induction of mitosis or by altering the cell viability (Fig. 9) . [ 3 H]-thymidine incorporation by pituitary cells was determined after 24 h of culture in the presence or absence of activin (10 À8 M) or GnRH (10 À8 M during the last 3 h) in serum-free medium. Activin treatment (10 À8 M, 24 h) significantly increased [ 3 H]-thymidine incorporation by about 40% (P , 0.05). GnRH (10 À8 M, 3 h) had no effect on cell proliferation (Fig. 9 ). Metformin treatment (5 or 10 mM) slightly but significantly decreased basal and both activinstimulated and GnRH-stimulated [ 3 H]-thymidine incorporation by about 20%-40% depending on the treatment (Fig. 9) . Staining with trypan blue revealed that metformin treatment (10 mM, 24 or 48 h) had no effect on cell viability in presence or absence of activin or GnRH (data not shown). Thus, metformin decreases cell proliferation slightly but not sufficiently to explain the decrease in gonadotropin release.
DISCUSSION
Our results demonstrate that PRKA activation induced by metformin treatment strongly reduced LH and FSH secretion in response to GnRH and FSH release induced by activin in rat pituitary cells in culture. Our findings also indicate that metformin-induced PRKA activation reduces FSHb subunit mRNA expression in response to activin. Moreover, we have shown that metformin treatment reduced SMAD2 and MAPK3/1 phosphorylation in response to activin and GnRH, respectively. Together, these findings suggest that PRKA activation induced by metformin treatment decreases gonadotropin release induced by GnRH and activin and this is associated with inhibition of the MAPK3/1 and SMAD2 signaling pathways, respectively, in rat pituitary cells (Fig. 10) .
The decrease in gonadotropin release in response to GnRH or activin observed in rat primary pituitary cells treated with metformin is consistent with in vivo results in human. Indeed, the treatment with metformin of women with PCOS leads to decreases in serum LH concentration [11, 12, 14] . Furthermore, in these latter conditions, the basal FSH levels are unchanged, suggesting a specific reduction of LH by metformin. In our in vitro study, metformin treatment decreased FSH secretion in response to GnRH or activin. However, we used cultured rat pituitary cells and a high dose of metformin, corresponding to about 250-1000 times that used in patients [36] . The molecular mechanisms of metformin action are not well understood. In hepatocytes, it has been shown that the cellular uptake of metformin is facilitated by the organic cation transporter 1 (SLC22A1, also known as OCT1). Consistent with this report, deletion of the Slc22a1 gene in mouse dramatically reduces metformin uptake in hepatocytes, and humans carrying reduced function polymorphisms of the SLC22A1 gene display an impaired effect of metformin [37] . Thus, we can suppose that in primary rat pituitary cells, SLC22A1 is weakly expressed and consequently we need high doses of metformin to obtain a biological effect. Thus, our results suggest that metformin could affect gonadotropin release in rat pituitary cells. Furthermore, these effects could be mediated by a modulation of GnRH or activin signaling because no effect of metformin on gonadotropin secretion is observed in the basal state. In the pituitary gonadotroph cell line LbT2, treatment with metformin (50 lM) has no effect on the basal promoter activities of either the FSHb or LHb-gonadotropin subunit, whereas it increases GnRH-induced FSHB and LHB promoter activities [14] . Even if the results of this latter study are not concordant with a reduction in the LH release observed in vivo in PCOS patients, they suggest that the effect of metformin treatment on LH secretion could be indirect and involve GnRH signaling at the gonadotroph cell level. The precise sites of action of metformin on gonadotropin-secreting cells and the mechanisms involved are not fully understood. We have found that metformin treatment (10 mM) does not affect LH and FSHb subunit mRNA expression in response to GnRH (data not shown) but it significantly decreases activin-stimulated FSHb subunit mRNA levels. Thus, metformin may decrease activin-induced FSH release by inhibiting FSHb subunit mRNA levels.
In various cell types, the effects of metformin are known to be mediated by PRKA activation. Metformin is shown to stimulate PRKA in the liver, in muscle [30, 38] , and also in reproductive tissues including the ovary [9, 29] . In contrast, metformin inhibits PRKA in the hypothalamus [18] . In the present study, we identified by RT-PCR and Western blot the expression of all three subunits (a, b, and c) of PRKA necessary for the formation of a heterotrimeric complex in the rat pituitary, which suggests that the enzyme can be effective in these cells and may mediate the effect of metformin on gonadotropin secretion. Furthermore, we localized the PRKAA1 subunit in the different pituitary population cells. PRKAA1 is mainly present in gonadotroph and thyrotroph cells and is less abundant in somatotroph and lactotroph cells. In contrast, it is undetectable in corticotroph cells, in agreement with a previous study that did not detect the PRKAA1 mRNA by RT-PCR in the AtT20 corticotroph cell line [39] . In this latter cell line, only PRKAA2 mRNA has been revealed. In the present study we have detected PRKAA1 in the gonadotroph cells; however, we don't know if these cells express the other subunits and what different a/b/c complexes are present. It has been shown that a/b/c combinations confer different properties to the PRKA complexes through differences in subcellular localization and signaling functions [40] . Thus, the specific subunit composition of PRKA in gonadotroph cells could be important to determine a specialized cellular and systemic response to different metabolic stresses. The presence of PRKA in rat gonadotroph cells is consistent with results showing that M activin in serum-free medium. Total RNA was prepared, and a Northern blot was carried out using specific rat probes for the b subunits of FSH. As a control, the membranes were stripped and reprobed with 18S RNA to confirm equal loading. The FSHB:RN18S ratio was calculated. Values represent means 6 SEM (bar) from three independent experiments. Different letters indicate significant difference (P , 0.05).
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LbT2 cells possess a functional PRKA pathway [20] . Indeed, in these cells, PRKA activation by AICAR, an AMP analog, enhances the phosphorylation of PRKA (Thr172) and ACACA (Ser79), a downstream target of PRKA. In the present study, we show for the first time that metformin treatment increases PRKAA Thr172 phosphorylation after 60 and 120 min of stimulation, consistent with an increase in ACACA phosphorylation at Ser79 in rat pituitary cells. Furthermore, metformin significantly decreases the release of LH and FSH induced by GnRH and the secretion of FSH in response to activin. We therefore suggest that these effects of metformin on gonadotropin production are mediated by PRKAA in rat pituitary cells. We have tested this hypothesis by using Comp C in rat pituitary cells, assessing LH and FSH release. Comp C is a cellpermeable pyrrazolopyrimidine compound that can act as a reversible and ATP-competitive inhibitor of PRKA [30] . However, several studies have reported inhibition of various biological events by Comp C independently of PRKA inhibition [41, 42] (for reviews see [43] ). Despite the uncertain specificity of this pharmacological inhibitor, various reports suggest that in specific conditions Comp C inhibits PRKA with expected results. For example, the genetic approach combined with the pharmacological approach furthers the PRKA-specific action of Comp C during stroke, as the effect of the pharmacological inhibitor has been lost in PRKAalpha2 knockout mice [44] (cited by [43] ). The metformin-induced decrease in gonadotropin secretion is reversed by Comp C. Thus, PRKAA is essential for the effects of metformin on GnRH-induced LH and FSH secretion and on FSH release in response to activin. This is consistent with a previous report showing that an acute AICAR treatment blocks GnRHstimulated LH secretion without changing cellular LH content [20] . In the present study we have determined the effect of metformin (48 h) on the release of gonadotropin in response to 3 h of continuous GnRH stimulation. In these conditions, we do not observe an effect of GnRH on the levels of mRNA expression of LHb and FSHb subunits. However, it is well known that gonadotropin subunit transcription rates increase following only exogenous GnRH pulses and not continuous GnRH stimulation [28] . Effects of GnRH on intracellular À8 M follistatin for 24 h, cells in serum-free medium were treated with exogenous 10 À8 M activin for indicated times. Total proteins (40 lg) from freshly lysed rat pituitary cells were electrophoresed on 10% SDS-polyacrylamide gels and then transferred to nitrocellulose membranes. Phosphorylation of SMAD2, MAPK3/1, and AKT was analyzed with polyclonal antibodies raised against phospho-SMAD2, MAPK3/1, and AKT, respectively. To determine the level of phosphorylation, all the blots were stripped and reprobed with antibodies against SMAD2, AKT, MAPK1, and MAPK14 proteins. D, E) Primary rat pituitary cells were incubated with 10 À8 M GnRH in serum-free medium for indicated times. Immunoblot to detect phosphorylation of MAPK3/1 and MAPK14 was performed as described above. To determine the level of phosphorylation, all the blots were stripped and reprobed with antibodies against MAPK1 and MAPK14 total proteins. The ratio of phosphorylation to total protein was determined and plotted as the percentage of stimulation as compared with the control (unstimulated cells). Values represent means 6 SEM from three independent experiments. Bars with different letters are significantly different (P , 0.05). signaling pathways have been described in detail and particularly with sustained stimulation. GnRH acts via seven transmembrane receptors on pituitary gonadotrophs to stimulate phospholipase C, mobilize calcium, and activate protein kinase C isozymes. This leads to activation of MAPK pathways including MAPK3/1 and MAPK14 and calcium effectors such as calmodulin, and these in turn mediate the effects of GnRH on exocytotic gonadotropin secretion as well as its effects on expression of many genes [45] [46] [47] . In the present study, we have shown that the activation of PRKA by metformin treatment decreases GnRH-induced MAPK3/1 phosphorylation. Thus, the inhibition of the MAPK3/1 pathway mediated by PRKA activation could be the mechanism by which metformin alters GnRH-and activin-induced gonadotropin release. In murine aT3-1 and LbT2 gonadotroph cells, the locus of action of MAPK3/1 is specifically mapped to early growth response 1 DNA binding sites within the LHb subunit gene proximal promoter [48] . As expected, in the present study we have observed that a continuous stimulation for 3 h of GnRH did not affect LHb and FSHb subunit mRNA levels [28] . However, it is strange that the reduction of MAPK3/1 signaling following metformin and GnRH treatment has no effect on Lhb mRNA. We can hypothesis that the relationship between MAPK3/1 activation and Lhb gene expression or the time course of action are different in gonadotroph cell lines and the cultured rat pituitary cells. Metformin could activate PRKA directly by reducing ATP levels through an inhibition of mitochondrial respiratory chain complex 1 as previously À8 M follistatin for 24 h, cells in serum-free medium were treated or not with metformin (10 mM) 6 exogenous 10 À8 M activin for 120 min. Lysates (50 lg) were resolved by SDS-PAGE, transferred to nitrocellulose, and probed with anti-phospho-SMAD2 and SMAD2. B) Rat pituitary cells were incubated in serum-free medium in the presence or in the absence of metformin (10 mM) 6 GnRH (10 À8 M) for 30 min. Lysates (50 lg) were resolved by SDS-PAGE, transferred to nitrocellulose, and probed with anti-phospho-SMAD2 and SMAD2. C and D) Level of SMAD2 (C) and MAPK3/1 (D) phosphorylation in rat pituitary cells infected with adenovirus constructs expressing a mutant PRKAA1 construct (Ad.aDN) or a GFP construct (Ad.GFP). Pituitary cells were infected with 100 pfu/cell of virus for 16 h in the presence (C) or absence (D) of 10 À8 M follistatin and then incubated with metformin (10 mM) 6 activin 10 À8 M for 120 min (C) or metformin (10 mM) 6 GnRH 10 À8 M for 30 min (D) in serum-free medium. Cell lysates were then prepared and resolved by SDS-PAGE. The proteins were transferred to nitrocellulose membranes and probed with anti-phospho-SMAD2 and then SMAD2 (C), or phospho-MAPK3/1 and then anti-MAPK1 (D). The immunoblots shown are representative of three independent experiments. Bands on the blots were quantified and the phosphorylated protein:total protein ratio is shown. The results are reported as means 6 SEM. Bars with different letters are significantly different (P , 0.05).
described [16, 30, [49] [50] [51] [52] and consequently inhibit trafficking and fusion of secretory vesicles that are ATP-dependent mechanisms. Furthermore, PRKA could also regulate the calcium concentration that is essential to induce secretion [47] .
By overproducing a mutant dominant-negative PRKAA1 with an adenovirus vector (Ad.aDN), we have shown that PRKAA is essential for the metformin-induced inhibition in FSHb subunit mRNA expression and SMAD2 phosphorylation in response to activin. Activin is considered as a potent stimulator of FSH expression and secretion in different species, including rat [53] . As expected, we did not observe an effect of activin on the LH secretion and mRNA expression in rat pituitary cells in vitro [54] . In different cell lines, activin is thought to signal primarily via the SMAD2/3 transduction pathway even if it can activate other signaling pathways including MAPK3/1 and AKT [31] . In the rat pituitary cells, we have shown that these signaling pathways are activated by activin. However, metformin treatment decreased only SMAD2 phosphorylation, and this was reversed by Ad.aDN. Based on our results, metformin-induced PRKA activation could regulate the Fshb mRNA expression in response to activin through an inhibition of SMAD2 phosphorylation. Indeed, some reports have shown that SMAD2 activation is involved in activininduced FSHb subunit expression [55] . We have found that metformin treatment inhibits cell growth in cultured rat pituitary cells in basal conditions and in response to activin without affecting cell viability. However, PRKAA does not seem to be essential for these effects, as the overproduction of a dominant-negative form of PRKAA1 does not restore the decrease in cell growth in response to metformin, despite the strong inhibition of PRKAA Thr172 phosphorylation (data not shown). Thus, metformin appears to stimulate or inhibit at least one molecule other than PRKA in rat pituitary cells, leading to a decrease in cell numbers. We have observed similar results in rat granulosa cells [9] .
In conclusion, the activation of PRKA by metformin in rat pituitary cells decreases GnRH-induced LH and FSH secretion and MAPK3/1 phosphorylation. Furthermore, it inhibits activin-induced FSH release and FSHb subunit mRNA. These findings significantly increase our understanding of the mechanism of action of metformin on pituitary cells. However, further investigations with human pituitary cells are required to determine whether the effects of metformin treatment in women with PCOS on LH secretion involve the activation of PRKA. 
